Alcedis

Alcedis is a clinical research organization (CRO) that provides a full-service portfolio for clinical trials, ranging from phase I through to drug approval, market access, and real-world evidence generation. Founded over three decades ago, the company differentiates itself by blending traditional CRO services with its proprietary Alcedis Platforms™, a technology ecosystem designed for multi-channel data integration, customized electronic case report forms (eCRF), and advanced data management. By leveraging in-house developed AI tools and secure, Germany-based cloud hosting, Alcedis enables agile, data-driven research workflows that emphasize high-quality data collection and streamlined clinical processes.

This approach helps pharmaceutical, biotechnology, and academic clients overcome the complexities of modern clinical research by providing customized scientific consulting, study design, and operational execution. The firm's integration of medical expertise with specialized digital health technology allows it to implement patient-centered solutions and efficiently manage diverse indications. Acquired by Huma Therapeutics in 2023, Alcedis continues to serve as a strategic partner that aims to accelerate medical progress through a combination of experienced clinical trial conduct and disruptive digital innovations that improve study transparency, data accuracy, and operational efficiency for global sponsors.